Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Foresite Capital Management IV, LLC (CIK 1704132) reported $290.2M across 6 reported positions in its SEC 13F filing for 2026-06-30. Largest positions: PHVS ($165.2M, 56.95%), CYTK ($60.9M, 20.98%), EIKN ($25.4M, 8.74%), RLAY ($23.4M, 8.06%), XENE ($9.7M, 3.33%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | PHVS | Pharvaris N.V. | $165.2M | 56.95% | 4.8M | Hold |
| 2 | CYTK | CYTOKINETICS INC | $60.9M | 20.98% | 714,695 | Added |
| 3 | EIKN | Eikon Therapeutics, Inc. | $25.4M | 8.74% | 1.9M | Hold |
| 4 | RLAY | Relay Therapeutics, Inc. | $23.4M | 8.06% | 1.2M | Added |
| 5 | XENE | Xenon Pharmaceuticals Inc. | $9.7M | 3.33% | 160,000 | Hold |
| 6 | CRNX | Crinetics Pharmaceuticals, Inc. | $5.6M | 1.93% | 150,000 | New |
| 7 | ALEC | Alector, Inc. | $0 | 0.00% | 0 | Exited |
| 8 | LYEL | Lyell Immunopharma, Inc. | $0 | 0.00% | 0 | Exited |
| 9 | MAZE | Maze Therapeutics, Inc. | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2026-06-30